This editorial refers to ‘In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles’, by M. Ricke-Hoch et al., pp. 1875–1886. Peripartum cardiomyopathy (PPCM) is a rare but potentially lethal condition which develops during the last month of pregnancy or more commonly, in the early postpartum period, resulting in heart failure with reduced left ventricular (LV) function. It affects between 1 in 900 and 1 in 4000 women with live births and is more common in blacks, who also appear to have a worse outcome.1 Clinically, it can manifest with the spectrum of heart failure presentations, from mild dyspnoea to fulminant cardiac failure requiring mechanical circulatory support, transplant, and even result in death from pump failure or fatal arrhythmias. Reported mortality rates range from 4% to 11% and recovery is unpredictable.1 Although 50–80% of patients recover with normalization of LV function, usually within 6 months, others may be left with long-term LV dysfunction.